ID 204927909 · FY 2017–2024 · 8 years
Georgian pharmaceutical importer and wholesale distributor. Limited public information available beyond the Reportal filing.
curated 2026-06-03reportal.ge
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 53,279 | 60,980 | 81,037 | 93,314 | 108,941 | 109,410 | 102,458 | 110,181 | +10.9% |
| Total COGS | -43,005 | -49,510 | -64,167 | -71,960 | -84,371 | -82,706 | -71,846 | -77,287 | +8.7% |
| Gross Profit | 10,274 | 11,470 | 16,869 | 21,354 | 24,570 | 26,704 | 30,612 | 32,894 | +18.1% |
| Gross Margin | 19.3% | 18.8% | 20.8% | 22.9% | 22.6% | 24.4% | 29.9% | 29.9% | |
| Total Operating Expenses | -3,627 | -8,821 | -14,895 | -14,758 | -16,822 | -19,403 | -26,454 | -25,933 | +32.4% |
| EBITDA | 6,647 | 2,649 | 1,975 | 6,595 | 7,748 | 7,302 | 4,157 | 6,960 | +0.7% |
| EBITDA Margin | 12.5% | 4.3% | 2.4% | 7.1% | 7.1% | 6.7% | 4.1% | 6.3% | |
| Total D&A | -552 | -610 | -734 | -3,488 | -4,066 | -4,351 | -4,927 | -5,045 | +37.2% |
| EBIT / Operating Income | 6,095 | 2,039 | 1,241 | 3,108 | 3,683 | 2,951 | -769 | 1,915 | -15.2% |
| Total Interest Income | 1,900 | 1,149 | 1,348 | 1,449 | 1,762 | 1,976 | 1,094 | 438 | -18.9% |
| Total Interest Expense | 0 | 0 | 0 | -1,193 | -1,328 | -1,280 | -1,558 | -1,714 | +9.5% |
| Total Other Income | -6 | 1,657 | 5,603 | 4,200 | 6,030 | 7,831 | 2,721 | 2,744 | nmf |
| Profit Before Tax | 7,989 | 4,845 | 8,193 | 7,563 | 10,147 | 11,477 | 1,488 | 3,384 | -11.5% |
| Total Income Tax | 0 | 0 | 0 | 0 | -8 | -39 | -24 | -20 | +37.5% |
| Net Profit / (Loss) | 4,753 | 4,803 | 8,147 | 6,728 | 9,084 | 10,163 | 153 | 2,894 | -6.8% |
| Net Margin | 8.9% | 7.9% | 10.1% | 7.2% | 8.3% | 9.3% | 0.1% | 2.6% |
Ownership & directors from companyinfo.ge (public corporate registry).